Sabine Knipp

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011, Lausanne, Switzerland
    Leuk Res 31:1585-7. 2007
  2. ncbi request reprint Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011 Lausanne, Switzerland
    Leuk Res 32:33-7. 2008
  3. ncbi request reprint Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
    Akira Matsuda
    Division of Hematology, Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, 350 0495, Japan
    Blood 106:2633-40. 2005
  4. ncbi request reprint Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7
    Sabine Knipp
    Haematologica 90:691-3. 2005
  5. ncbi request reprint Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
    Sabine Knipp
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 110:345-52. 2007
  6. ncbi request reprint Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Moorenstr 5, 40225 Dusseldorf, Germany
    Haematologica 91:1596-604. 2006
  7. ncbi request reprint Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS
    Akos Czibere
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Br J Haematol 135:355-7. 2006
  8. ncbi request reprint Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis
    Norman Putzki
    Department of Neurology, University Hospital Essen, Essen, Germany
    Mult Scler 12:363-6. 2006
  9. ncbi request reprint The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 106:112-9. 2006
  10. ncbi request reprint Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Ann Hematol 84:61-6. 2005

Detail Information

Publications11

  1. ncbi request reprint Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011, Lausanne, Switzerland
    Leuk Res 31:1585-7. 2007
    ..002 mg/l (0.027 micromol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia...
  2. ncbi request reprint Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome
    Sabine Knipp
    Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011 Lausanne, Switzerland
    Leuk Res 32:33-7. 2008
    ..00005). Median survival of patients with PB was not different from that of RAEB I. We therefore propose to consider patients with PB, regardless of medullary blast, as RAEB I...
  3. ncbi request reprint Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
    Akira Matsuda
    Division of Hematology, Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, 350 0495, Japan
    Blood 106:2633-40. 2005
    ..In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients...
  4. ncbi request reprint Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7
    Sabine Knipp
    Haematologica 90:691-3. 2005
    ..Long-term treatment with azathioprine seems to be associated with an increased risk of MDS and subsequent leukemic transformation...
  5. ncbi request reprint Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
    Sabine Knipp
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 110:345-52. 2007
    ..It is unclear whether intensive chemotherapy is beneficial to patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) if they are aged >/=60 years...
  6. ncbi request reprint Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes
    Ulrich Germing
    Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Moorenstr 5, 40225 Dusseldorf, Germany
    Haematologica 91:1596-604. 2006
    ..The aim of this study was a prospective validation of the World Health Organization (WHO) proposals for the classification of myelodysplastic syndromes (MDS) with respect to their prognostic relevance...
  7. ncbi request reprint Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS
    Akos Czibere
    Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Br J Haematol 135:355-7. 2006
    ..Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS...
  8. ncbi request reprint Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis
    Norman Putzki
    Department of Neurology, University Hospital Essen, Essen, Germany
    Mult Scler 12:363-6. 2006
    ..Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza. Long-term Aza therapy needs careful monitoring...
  9. ncbi request reprint The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Cancer 106:112-9. 2006
    ..Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro...
  10. ncbi request reprint Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
    Andrea Kuendgen
    Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Ann Hematol 84:61-6. 2005
    ..For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs. If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response...
  11. ncbi request reprint Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
    Luca Malcovati
    Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
    J Clin Oncol 25:3503-10. 2007
    ....